Evidence map›Paper›PMID 38426292›Full record

Trial reportHaematologica2024

Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.

Fredrik H Schjesvold, Heinz Ludwig, Sossana Delimpasi, Pawel Robak, Daniel Coriu, Waldemar Tomczak, Ludek Pour, Ivan Spicka, Meletios-Athanasios Dimopoulos, Tamas Masszi and 8 more

Open access · goldAbstract readClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 15 institutions in 12 countries.

Fredrik H SchjesvoldOslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway. fredrikschjesvold@gmail.com.
Heinz LudwigDepartment of Medicine I, Center for Medical Oncology and Hematology with Outpatient Department and Palliative Care, Wilhelminen Cancer Research Institute, Vienna.
Sossana DelimpasiBone Marrow Transplantation Unit and Department of Hematology, Evangelismos Hospital, Athens, Greece.
Pawel RobakDepartment of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic.
Daniel CoriuUniversity of Medicine and Pharmacy "Carol Davila", Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
Waldemar TomczakDepartment of Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin.
Ludek PourDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Babak Myeloma Group, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Ivan Spicka1st Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic.
Meletios-Athanasios DimopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Tamas MassziDepartment of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
Natalia G ChernovaNational Research Center for Haematology, Moscow, Russia.
Anna SandbergOncopeptides AB, Stockholm, Sweden.
Marcus ThuressonOncopeptides AB, Stockholm, Sweden.
Stefan NorinOncopeptides AB, Stockholm, Sweden.
Nicolaas A BakkerOncopeptides AB, Stockholm, Sweden.
Maria-Victoria MateosHospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain.
Paul G RichardsonDana-Farber Cancer Institute, Boston, MA.
Pieter SonneveldErasmus MC Cancer Institute, Rotterdam.
Oncopeptides (Sweden) · SECharles University · CZDana-Farber Cancer Institute · USErasmus MC Cancer Institute · NLEvangelismos Hospital · GRFederal State Institution Hematology Research Center · RUInstituto de Investigación Biomédica de Salamanca · ESInstitutul Clinic Fundeni · ROMasaryk University · CZMedical University of Lublin · PLNational and Kapodistrian University of Athens · GROslo University Hospital · NOSemmelweis University · HUUniversity Hospital Ostrava · CZWilhelminen Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsDexamethasoneMultiple MyelomaQuality of LifeAgedDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPhenylalanineRecurrenceTreatment OutcomeDexamethasonePhenylalanine

Identifiers

PMID38426292
PMCPMC11215352
OpenAlexW4392287333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.